Overview

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body. This study will also demostrate how safe the combined drugs are when used to treat patients with Stage 3 or Stage 4 melanoma (metastatic melanoma), which cannot be removed by surgery.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

James Graham Brown Cancer Center

Collaborator:

University of Louisville

Treatments:

Antibodies, Monoclonal
Ipilimumab